» Articles » PMID: 38515023

How Does the SARS-CoV-2 Reinfection Rate Change over Time? The Global Evidence from Systematic Review and Meta-analysis

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2024 Mar 22
PMID 38515023
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is a significant increase in the number of SARS-CoV-2 reinfection reports in various countries. However, the trend of reinfection rate over time is not clear.

Methods: We searched PubMed, Web of Science, Medline, Embase, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, and Wanfang for cohort studies, case-control studies, and cross-sectional studies up to March 16, 2023, to conduct a meta-analysis of global SARS-CoV-2 reinfection rate. Subgroup analyses were performed for age, country, study type, and study population, and time-varying reinfection rates of SARS-CoV-2 were estimated using meta-regression. The risk of bias was assessed using the Newcastle-Ottawa Scale and the Joanna Briggs Institute critical appraisal tool.

Result: A total of 55 studies involving 111,846 cases of SARS-CoV-2 reinfection were included. The pooled SARS-CoV-2 reinfection rate was 0.94% (95% CI: 0.65 -1.35%). In the subgroup analyses, there were statistically significant differences in the pooled reinfection rates by reinfection variant, and study type (P < 0.05). Based on meta-regression, the reinfection rate fluctuated with time.

Conclusion: Meta-regression analysis found that the overall reinfection rate increased and then decreased over time, followed by a period of plateauing and then a trend of increasing and then decreasing, but the peak of the second wave of reinfection rate was lower than the first wave. SARS-CoV-2 is at risk of reinfection and the Omicron variant has a higher reinfection rate than other currently known variants. The results of this study could help guide public health measures and vaccination strategies in response to the Coronavirus Disease 2019 (COVID-19) pandemic.

Citing Articles

SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study.

Toran-Monserrat P, Lamonja-Vicente N, Costa-Garrido A, Carrasco-Ribelles L, Quirant B, Boigues M JMIR Public Health Surveill. 2024; 10:e56926.

PMID: 39648969 PMC: 11606241. DOI: 10.2196/56926.


Prediction of SARS-CoV-2 infection cases based on the meta-SEIRS model.

Zhu W, Tang X, Chen Y, Chen M, Han X, Xie Y Epidemiol Infect. 2024; 152:e144.

PMID: 39552127 PMC: 11574606. DOI: 10.1017/S0950268824001274.


Rate, risk factors, and clinical outcomes of SARS-CoV-2 reinfection vs. primary infection in readmitted COVID-19 patients in Iran: a retrospective cohort study.

Shahrbaf M, Alimohamadi Y, Yousefi Arfaei R, Salesi M, Izadi M, Raei M Front Public Health. 2024; 12:1480805.

PMID: 39484354 PMC: 11524883. DOI: 10.3389/fpubh.2024.1480805.


Role of Vaccination Strategies to Host-Pathogen Dynamics in Social Interactions.

Gonzaga M, de Oliveira M, Atman A Entropy (Basel). 2024; 26(9).

PMID: 39330073 PMC: 11431798. DOI: 10.3390/e26090739.


Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.

Chung Y, Lam C, Tan P, Tsang H, Wong S Int J Mol Sci. 2024; 25(15).

PMID: 39125722 PMC: 11312261. DOI: 10.3390/ijms25158155.


References
1.
Dillner P, Eggenschwiler L, Rutjes A, Berg L, Musy S, Simon M . Incidence and characteristics of adverse events in paediatric inpatient care: a systematic review and meta-analysis. BMJ Qual Saf. 2022; 32(3):133-149. PMC: 9985739. DOI: 10.1136/bmjqs-2022-015298. View

2.
Finch E, Lowe R, Fischinger S, de St Aubin M, Siddiqui S, Dayal D . SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. PLoS Biol. 2022; 20(2):e3001531. PMC: 8865659. DOI: 10.1371/journal.pbio.3001531. View

3.
Graham M, Sudre C, May A, Antonelli M, Murray B, Varsavsky T . Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021; 6(5):e335-e345. PMC: 8041365. DOI: 10.1016/S2468-2667(21)00055-4. View

4.
Mao Y, Wang W, Ma J, Wu S, Sun F . Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021; 135(2):145-152. PMC: 8769121. DOI: 10.1097/CM9.0000000000001892. View

5.
Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View